290 related articles for article (PubMed ID: 30617217)
1. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.
Best S; Hashiguchi T; Kittai A; Bruss N; Paiva C; Okada C; Liu T; Berger A; Danilov AV
Blood Adv; 2019 Jan; 3(1):51-62. PubMed ID: 30617217
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Zhuang J; Shirazi F; Singh RK; Kuiatse I; Wang H; Lee HC; Berkova Z; Berger A; Hyer M; Chattopadhyay N; Syed S; Shi JQ; Yu J; Shinde V; Tirrell S; Jones RJ; Wang Z; Davis RE; Orlowski RZ
Blood; 2019 Apr; 133(14):1572-1584. PubMed ID: 30737236
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Best S; Liu T; Bruss N; Kittai A; Berger A; Danilov AV
Leuk Lymphoma; 2019 Dec; 60(12):2946-2950. PubMed ID: 31111763
[TBL] [Abstract][Full Text] [Related]
4. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
5. Oroxin B selectively induces tumor-suppressive ER stress and concurrently inhibits tumor-adaptive ER stress in B-lymphoma cells for effective anti-lymphoma therapy.
Yang P; Fu S; Cao Z; Liao H; Huo Z; Pan Y; Zhang G; Gao A; Zhou Q
Toxicol Appl Pharmacol; 2015 Oct; 288(2):269-79. PubMed ID: 26253462
[TBL] [Abstract][Full Text] [Related]
6. GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death.
Liu G; Yu J; Wu R; Shi L; Zhang X; Zhang W; Zhong X; Wang Y; Li H; Shen Y; Wu C; Yu R; Niu M; Liu X
Cell Death Dis; 2021 Jul; 12(8):733. PubMed ID: 34301924
[TBL] [Abstract][Full Text] [Related]
7. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
[TBL] [Abstract][Full Text] [Related]
8. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
[TBL] [Abstract][Full Text] [Related]
9. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
11. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
14. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
[TBL] [Abstract][Full Text] [Related]
15. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
[TBL] [Abstract][Full Text] [Related]
16. Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.
Shi X; Lan X; Chen X; Zhao C; Li X; Liu S; Huang H; Liu N; Zang D; Liao Y; Zhang P; Wang X; Liu J
Sci Rep; 2015 Apr; 5():9694. PubMed ID: 25853502
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
18. The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.
Rui YN; Xu Z; Chen Z; Zhang S
Autophagy; 2015; 11(5):812-32. PubMed ID: 25984893
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
20. Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570.
Pellegrini P; Selvaraju K; Faustini E; Mofers A; Zhang X; Ternerot J; Schubert A; Linder S; D Arcy P
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]